TerminatedPhase 4

Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH

Stopped: because of withdrawal of Avandia sale due to its risks outweigh its benefits

26 participantsStarted 2004-01

Plain-language summary

This study is to evaluate the effects of Rosiglitazone, insulin sensitizer and alpha-lipoic acid, antioxidant on patients with pathologically proved NASH (non-alcoholic steato-hepatitis).

Who can participate

Age range20 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * the patients with pathologically proved NASH (non-alcoholic steato-hepatitis) Exclusion Criteria: * alcohol consumption \> 20g/day * viral hepatitis B and C * autoimmune hepatitis * Wilson's disease * hemochromatosis * alpha-1 antitrypsin deficiency * breast-feeding or pregnant females * subjects planning to become pregnant * severe comorbid medical conditions (such as severe cardiac, pulmonary, renal or psychological problems) * those not consenting for the study

What they're measuring

Histological evaluation

Timeframe: 24 weeks

Trial details

NCT IDNCT01406704

SponsorSeoul St. Mary's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-12

View on ClinicalTrials.gov More NASH (Non-alcoholic Steato-hepatitis) trials